
浏览全部资源
扫码关注微信
纸质出版日期:2015
移动端阅览
王风秀, 张廷明, 丁长玲. 清肺化浊汤辅助治疗急性加重期慢性阻塞性肺疾病(痰热壅肺证)50例[J]. 中国实验方剂学杂志, 2015,21(3):187-190.
WANG Feng-xiu, ZHANG Ting-ming, DING Chang-ling. Qingfei Huazhuo Treating 50 Chronic Obstructive Pulmonary Disease Patients During Acute Exacerbation Period[J]. Chinese journal of experimental traditional medical formulae, 2015, 21(3): 187-190.
王风秀, 张廷明, 丁长玲. 清肺化浊汤辅助治疗急性加重期慢性阻塞性肺疾病(痰热壅肺证)50例[J]. 中国实验方剂学杂志, 2015,21(3):187-190. DOI: 10.13422/j.cnki.syfjx.2015030187.
WANG Feng-xiu, ZHANG Ting-ming, DING Chang-ling. Qingfei Huazhuo Treating 50 Chronic Obstructive Pulmonary Disease Patients During Acute Exacerbation Period[J]. Chinese journal of experimental traditional medical formulae, 2015, 21(3): 187-190. DOI: 10.13422/j.cnki.syfjx.2015030187.
目的: 探讨清肺化浊汤辅助治疗急性加重期慢性阻塞性肺疾病(AECOPD)(痰热壅肺证)的临床疗效及对血清超氧化物歧化酶(SOD)
丙二醛(MDA)
白细胞介素-10(IL-10)和肿瘤坏死因子-α(TNF-α)的影响。方法: 100例AECOPD患者采用随机数字法分为对照组和中药组各50例。对照组给予控制性氧疗
抗感染
激素
支气管舒张剂等综合治疗措施。中药组在对照组治疗的基础上加用清肺化浊汤
1剂/d
两组疗程均为2周。对咯痰、咳嗽、气喘及肺部湿啰音等主要症状进行治疗前后评分;采用《呼吸功能状态和呼吸困难问卷修改版》(PFSDQ-M)量表进行治疗前后生存质量评价;进行治疗前后肺功能评价;检测治疗前后血清SOD
MDA
IL-10及TNF-α水平。结果: 经Ridit分析
中药组临床疗效优于对照组
差异有统计学意义(P<0.05);治疗后中药组咯痰、咳嗽、气喘及肺部啰音评分低于对照组(P<0.01);治疗后中药组生存质量评分均低于对照组(P<0.01);治疗后对照组呼气容积(FEV1)和呼气容积占用力肺活量(FEV1/FVC)有所改善
但差异无统计学意义;中药组治疗后FEV1和FEV1/FVC较治疗前有所增高
并高于对照组(P<0.01);治疗后中药组血清TNF-α和MDA水平低于对照组(P<0.01);IL-10和SOD水平高于对照组(P<0.01)。结论: 清肺化浊汤能减轻AECOPD(痰热壅肺证)临床症状、改善肺功能
提高患者的生活质量
其作用机制可能与调节氧化/抗氧化系统
抑制炎症反应有关。
Objective: To discuss the curative efficacy of Qingfei Huazhuo decoction in assisted-treating acute exacerbation of chronic obstructive pulmonary disease (AECOPD) of phlegm heat obstructing lung syndrome and to investigate its influence on serum superoxide dismutase (SOD)
malondialdehyde (MDA) and interleukin-10 (IL-10) and tumor necrosis factor-α (TNF-α). Method: One hundred AECOPD patients were randomly divided into the control group (50 cases) and the traditional Chinese medicine group (50 cases) by random number table. Patients in the control group received comprehensive treatment therapy including controlling oxygen therapy
infection resistance
hormone and bronchial relaxation. Based on the treatment of control group
patients in traditional Chinese medicine group added Qingfei Huazhuo decoction
1 does daily. All patients received 2-week treatment. Scores of the main symptoms including cough up phlegm
cough
asthma and pulmonary rales were recorded before and after treatment. Quality of life through respiratory function state and difficulty in breathing questionnaire-modified (PFSDQ-M) were evaluated. The pulmonary function was appraised before and after treatment. Levels of serum SOD
MDA
IL-10 and TNF-α were tested before and after therapy. Result: The clinical effect in traditional Chinese medicine group was superior to that in control group with statistically significant difference (P<0.05). After treatment
scores of cough up phlegm
cough
asthma and pulmonary rales in traditional Chinese medicine group were less than those in control group (P<0.01). Quality of life score in traditional Chinese medicine group was inferior to that in control group (P<0.01). Forced expiratory volume in one second(FEV1) and forced expiratory volume accounted for forced vital capacity(FEV1/FVC) in control group improved
but there was no statistically significant difference. Expected value of FEV1 and FEV1/FVC in control group rose as compared with that before therapy
while the rose degree was higher than that in control group (P<0.01). Levels of serum TNF-α and MDA in traditional Chinese medicine group were lower than those in control group (P<0.01). Besides
the IL-10 and SOD levels were higher than those in control group (P<0.01). Conclusion: Qingfei Huazhuo decoction could reduce clinical symptoms of AECOPD of phlegm heat obstructing lung syndrome
improve lung function and patient's life of quality. The mechanism of action may be related to adjusting oxidation/antioxidant system and inhibiting inflammatory reaction.
0
浏览量
4
下载量
2
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010802024621